DE60239428D1 - - Google Patents
Info
- Publication number
- DE60239428D1 DE60239428D1 DE60239428T DE60239428T DE60239428D1 DE 60239428 D1 DE60239428 D1 DE 60239428D1 DE 60239428 T DE60239428 T DE 60239428T DE 60239428 T DE60239428 T DE 60239428T DE 60239428 D1 DE60239428 D1 DE 60239428D1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- relates
- present
- coa reductase
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229960004796 rosuvastatin calcium Drugs 0.000 abstract 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2002/005213 WO2004052867A1 (en) | 2002-12-10 | 2002-12-10 | Process for the preparation of rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60239428D1 true DE60239428D1 (OSRAM) | 2011-04-21 |
Family
ID=32500442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60239428T Expired - Lifetime DE60239428D1 (OSRAM) | 2002-12-10 | 2002-12-10 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7566782B2 (OSRAM) |
| EP (1) | EP1578733B1 (OSRAM) |
| CN (1) | CN1742000A (OSRAM) |
| AT (1) | ATE501126T1 (OSRAM) |
| AU (1) | AU2002348881A1 (OSRAM) |
| CA (1) | CA2509619A1 (OSRAM) |
| DE (1) | DE60239428D1 (OSRAM) |
| DK (1) | DK1578733T3 (OSRAM) |
| HU (1) | HUP0500851A3 (OSRAM) |
| SI (1) | SI1578733T1 (OSRAM) |
| WO (1) | WO2004052867A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159741A0 (en) | 2001-07-13 | 2004-06-20 | Astrazeneca Uk Ltd | Preparation of aminopyrimidine compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| CA2657076A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| US7777034B2 (en) | 2003-11-24 | 2010-08-17 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| CA2546894C (en) | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| ES2389565T3 (es) | 2005-02-22 | 2012-10-29 | Teva Pharmaceutical Industries Ltd. | Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas |
| US20090124803A1 (en) * | 2005-03-22 | 2009-05-14 | Pandurang Balwant Deshpande | Process for preparation of rosuvastatin |
| EP1869005A1 (en) * | 2005-04-04 | 2007-12-26 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
| CN1307187C (zh) * | 2005-05-16 | 2007-03-28 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
| EP1893585A1 (en) * | 2005-06-01 | 2008-03-05 | Fermion Oy | Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide |
| CN102807530B (zh) * | 2005-06-24 | 2015-08-05 | 力奇制药公司 | 制备不含杂质的无定型罗苏伐他汀钙的方法 |
| CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| MX2007004427A (es) | 2005-08-16 | 2007-06-14 | Teva Pharma | Intermedio de rosuvastatina cristalina. |
| MX2007006647A (es) * | 2005-10-04 | 2007-07-25 | Teva Pharma | Preparacion de rosuvastatina. |
| WO2008053334A2 (en) | 2006-10-31 | 2008-05-08 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
| WO2008072078A1 (en) * | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
| AU2008212622B2 (en) | 2007-02-08 | 2011-01-27 | Aurobindo Pharma Limited | An improved process for preparation of rosuvastatin calcium |
| WO2009009152A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and their preparation |
| KR101157314B1 (ko) | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
| EP2336116A1 (en) | 2009-12-16 | 2011-06-22 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| CN105153010B (zh) * | 2010-07-01 | 2018-06-08 | 柳韩洋行 | HMG-CoA还原酶抑制剂及其中间体的制备方法 |
| WO2012011129A2 (en) * | 2010-07-22 | 2012-01-26 | Msn Laboratories Limited | Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| AU2012260605B2 (en) * | 2011-05-20 | 2015-02-19 | Astrazeneca Uk Limited | Pharmaceutical composition of rosuvastatin calcium |
| CN102358747B (zh) * | 2011-08-30 | 2012-09-19 | 浙江宏元药业有限公司 | 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法 |
| CN103601687A (zh) * | 2013-11-25 | 2014-02-26 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| WO2015074328A1 (zh) * | 2013-11-25 | 2015-05-28 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| CN104230990B (zh) * | 2014-08-15 | 2016-05-11 | 新发药业有限公司 | 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用 |
| CN104630297B (zh) * | 2014-12-10 | 2018-07-06 | 江南大学 | 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
-
2002
- 2002-12-10 DE DE60239428T patent/DE60239428D1/de not_active Expired - Lifetime
- 2002-12-10 US US10/537,859 patent/US7566782B2/en not_active Expired - Fee Related
- 2002-12-10 AT AT02781613T patent/ATE501126T1/de active
- 2002-12-10 WO PCT/IB2002/005213 patent/WO2004052867A1/en not_active Ceased
- 2002-12-10 AU AU2002348881A patent/AU2002348881A1/en not_active Abandoned
- 2002-12-10 HU HU0500851A patent/HUP0500851A3/hu unknown
- 2002-12-10 CN CNA028301951A patent/CN1742000A/zh active Pending
- 2002-12-10 DK DK02781613.1T patent/DK1578733T3/da active
- 2002-12-10 EP EP02781613A patent/EP1578733B1/en not_active Expired - Lifetime
- 2002-12-10 SI SI200230942T patent/SI1578733T1/sl unknown
- 2002-12-10 CA CA002509619A patent/CA2509619A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2509619A1 (en) | 2004-06-24 |
| DK1578733T3 (da) | 2011-06-14 |
| ATE501126T1 (de) | 2011-03-15 |
| SI1578733T1 (sl) | 2011-07-29 |
| HUP0500851A2 (en) | 2007-08-28 |
| US20060149065A1 (en) | 2006-07-06 |
| EP1578733B1 (en) | 2011-03-09 |
| CN1742000A (zh) | 2006-03-01 |
| WO2004052867A1 (en) | 2004-06-24 |
| US7566782B2 (en) | 2009-07-28 |
| AU2002348881A1 (en) | 2004-06-30 |
| EP1578733A1 (en) | 2005-09-28 |
| HUP0500851A3 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60239428D1 (OSRAM) | ||
| AU2003240517A1 (en) | Substituted pyrrolines as kinase inhibitors | |
| MXPA04008613A (es) | N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv. | |
| YU5503A (sh) | Nesteroidni supresori zapaljenja | |
| PL373645A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
| WO2012002741A3 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
| BG107856A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| TW200518756A (en) | Process for preparation of rosuvastatin calcium | |
| AU2003225295A1 (en) | Substituted pyrroline kinase inhibitors | |
| MY147435A (en) | Process for the production of atorvastatin calcium in amorphous form | |
| MXPA04007396A (es) | Proceso para la elaboracion de inhibidores de reductasa hmg-coa. | |
| TW200634018A (en) | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses | |
| EA200401533A1 (ru) | Способ получения росувастатина | |
| BRPI0413468A (pt) | inibidores de hmg-coa redutase baseados em pirrol | |
| EP1205189A3 (en) | Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth | |
| TW200617019A (en) | A process for the preparation of 7α-alkylated 19-norsteroids | |
| IL174469A0 (en) | Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics | |
| PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
| TW200640914A (en) | Novel processes for the preparation of a benzofuran | |
| YU101402A (sh) | Visoko prečišćeni preparati simvastatina | |
| WO2004048380A8 (en) | Process for the synthesis of ganciclovir | |
| TW200724688A (en) | Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof | |
| DE60233899D1 (de) | Neue boronatester | |
| MXPA02011762A (es) | Proceso para la preparacion de compuestos metales de transicion y su empleo para la polimerizacion de olefinas. | |
| MXPA03010498A (es) | Proceso para la preparacion de imipenem. |